29 results on '"Reenaers, C."'
Search Results
2. P322 Compared Efficacy of Second-Line Treatments for Ulcerative Colitis After Failure of Vedolizumab in First-Line Treatment: A Retrospective Multicenter Study
3. P397 Distinct blood protein profiles associated with ileal and colonic ulcers in Crohn’s disease
4. Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease–a Case Series
5. P732 Impact of different types of physical activity in inflammatory bowel disease
6. P443 Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort Study
7. Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study
8. How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study
9. DOP36 Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter study
10. P234 Remission state in Inflammatory Bowel Disease patients on anti TNF or vedolizumab: a confocal endomicroscopy study
11. P350 Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study
12. P558 Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study
13. Progressing Towards the Implementation of a Treat-To-Target Strategy in Perianal Crohn’s Disease
14. P293 Local Mesenchymal Stem Cells injection in Crohn’s disease strictures: a phase I-II, open-label clinical study
15. P286 Bariatric surgery in inflammatory bowel disease: outcome and safety from a GETAID registry population
16. P347 Vedolizumab for primary sclerosing cholangitis associated with inflammatory bowel disease: A multicentre cohort study from the GETAID
17. P723 Effectiveness and persistence of vedolizumab in patients with Inflammatory bowel Disease: Results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)
18. P612 Immunosuppressive co-treatment with infliximab and adalimumab is not superior to anti-TNF monotherapy to prevent treatment failure and treatment discontinuation in ulcerative colitis
19. P057 Proteomic analysis highlights divergences and convergences between ileal and colonic pathological processes involved in Crohn’s ulcers
20. DOP011 Risk of opportunistic infection in healthcare personnel with inflammatory bowel disease: a case-control study of the GETAID
21. P181 Natural history of non-severe IBD at diagnosis
22. P653 Genetic predictors of non reversible tissue damage in inflammatory bowel disease
23. P262 Clinical outcome of perianal Crohn's disease: Natural history and impact of medical and surgical strategies over time
24. P358 Risk of incident cancer in patients with inflammatory bowel disease starting anti-TNF therapy while having prior malignancy within past 5 years (GETAID survey)
25. OP15 Immunosuppressive co-treatment with adalimumab (ADA) may be more effective than ADA monotherapy for maintaining remission in Crohn's disease (CD)
26. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids
27. Should Patients Under Long-term Anti-TNF Therapies be Followed for Tuberculosis Contamination?
28. P283 INCREASED EXPRESSION OF RANKL, RANK AND OSTEOPROTEGERIN IN INFLAMMATORY BOWEL DISEASES
29. Increased expression of receptor activator of NF-κB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.